^
    CANCER:

    Lung Non-Squamous Non-Small Cell Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    PD1 inhibitor
    pembrolizumab
    sintilimab
    nivolumab
    		0
    PD1 inhibitor
    cemiplimab-rwlc
    toripalimab-tpzi
    tislelizumab
    camrelizumab
    pucotenlimab
    bevacizumab
    		1
    VEGF-A inhibitor
    bevacizumab-maly
    bevacizumab-tnjn
    bevacizumab-awwb
    PD-L1 inhibitor
    		2
    PD-L1 inhibitor
    atezolizumab
    durvalumab
    alectinib
    		3
    ALK inhibitor
    crizotinib
    ceritinib
    ensartinib
    EGFR inhibitor
    osimertinib
    		4
    EGFR inhibitor
    furmonertinib
    gefitinib
    erlotinib
    5
    VEGF-A inhibitor, PD1 inhibitor
    nivolumab + bevacizumab
    sintilimab + Byvasda (bevacizumab biosimilar)
    6
    VEGFR-2 inhibitor, PD1 inhibitor
    camrelizumab + rivoceranib
    7
    VEGF-A inhibitor, EGFR inhibitor
    bevacizumab + erlotinib
    8
    MEK inhibitor
    binimetinib
    9
    VEGF-A inhibitor, Angiogenesis inhibitor
    SIBP-04 (bevacizumab biosimilar)
    PSB205
    		10
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    MEDI5752
    11
    EGFR inhibitor, Multi-tyrosine kinase inhibitor
    anlotinib + icotinib
    12
    Multi-tyrosine kinase inhibitor
    anlotinib
    13
    VEGF-A inhibitor, ALK inhibitor
    bevacizumab + alectinib
    14
    KRAS G12C inhibitor
    sotorasib
    EP
    VC
    GC
    		15
    Chemotherapy
    ABCP
    GemCarbo
    CaT
    GemVin
    GT
    16
    Immunotherapy
    Immunotherapy
    17
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    18
    PD-L1 inhibitor, VEGF-A inhibitor
    bevacizumab + atezolizumab
    19
    c-MET inhibitor, EGFR inhibitor
    amivantamab-vmjw
    20
    PD-L1 inhibitor, CTLA4 inhibitor
    durvalumab + tremelimumab
    21
    THF dehydrogenase inhibitor, DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + pemetrexed
    22
    THF dehydrogenase inhibitor, Tubulin polymerization promoter, Thymidylate synthase inhibitor
    carboplatin + pemetrexed
    23
    DNA synthesis inhibitor
    cisplatin
    24
    Microtubule stabilizer, Tubulin polymerization promoter
    carboplatin + docetaxel
    docetaxel
    25
    THF dehydrogenase inhibitor, Thymidylate synthase inhibitor
    pemetrexed
    26
    c-MET-targeted antibody-drug conjugate, Microtubule inhibitor
    ABBV-399
    27
    Microtubule stabilizer, Tubulin polymerization promoter, GEF-H1 activator
    docetaxel + BPI 2358
    28
    CEACAM5-targeted antibody-drug conjugate, Microtubule inhibitor
    SAR408701
    29
    c-MET-targeted antibody-drug conjugate, EGFR inhibitor, Microtubule inhibitor
    erlotinib + ABBV-399
    30
    AXL inhibitor, PD1 inhibitor
    pembrolizumab + BGB324
    31
    VEGFR-2 inhibitor, CEACAM5-targeted antibody-drug conjugate, Microtubule inhibitor
    ramucirumab + SAR408701
    32
    PD-L1 inhibitor, VEGF-A inhibitor, TGF-β R2 kinase inhibitor
    bevacizumab + SHR-1701
    33
    CDK4 inhibitor, PD1 inhibitor, CDK6 inhibitor
    pembrolizumab + abemaciclib
    34
    VEGFR inhibitor, PD1 inhibitor
    sintilimab + fruquintinib
    35
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    afatinib
    36
    VEGF-A inhibitor, HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    bevacizumab + afatinib
    37
    ALK inhibitor, EGFR inhibitor
    brigatinib
    38
    CEACAM5-targeted antibody-drug conjugate, PD1 inhibitor, Microtubule inhibitor
    pembrolizumab + SAR408701
    No biomarker
    EGFR mutation
    EGFR exon 19 deletion
    EGFR wild-type
    EGFR exon 20 insertion
    EGFR L858R
    EGFR T790M
    EGFR negative
    EGFR expression
    ALK fusion
    ALK wild-type
    ALK positive
    ALK rearrangement
    ALK mutation
    PD-L1 overexpression
    PD-L1 expression
    MHC-II overexpression + PD-L1 negative
    MHC-II overexpression + PD-L1 underexpression
    PD-L1 underexpression
    PD-L1 negative
    Chr del(9p) + PD-L1 overexpression
    KRAS mutation
    KRAS G12C
    KRAS G12V
    ROS1 wild-type
    ROS1 rearrangement
    ROS1 fusion
    EGFR wild-type + MET overexpression
    CEACAM5 overexpression
    CEACAM5 expression
    MET overexpression + EGFR wild-type
    EGFR exon 19 deletion + VEGFA-L
    PD-L1 overexpression + KRAS mutation
    MET positive
    MET overexpression
    EGFR L858R + VEGFA-L
    KRAS mutation + PD-L1 negative
    KEAP1 mutation
    EGFR wild-type + ALK wild-type + STK11 mutation
    EGFR negative + ALK negative
    EML4-ALK fusion + ALK positive
    STK11 mutation
    MAP2K1 mutation
    MGAM mutation
    TTF1 negative
    EGFR mutation + PD-L1 expression
    TMB-H
    TP53 mutation
    PD-L1 overexpression + KRAS G12C + TP53 mutation
    EGFR mutation + KRAS mutation
    STK11 deletion + TTF1 positive
    NRAS mutation
    NKX2-1 expression + PD-L1 expression
    STK11 mutation + KEAP1 mutation
    HER-2 negative + PD-L1 expression
    KEAP1 deletion + KRAS mutation
    STK11 deletion + KRAS mutation
    miR-34a underexpression
    miR-200-c overexpression
    Chr del(9)(p21.3)